CD20 antibodies: type II to tango?

Affiliations

Free article

Comment

Marinus H J van Oers. Blood. 2012.

Free article

. 2012 May 31;119(22):5061-3.

doi: 10.1182/blood-2012-04-420711.

No abstract available

Comment on

Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients.
Salles G, Morschhauser F, Lamy T, Milpied N, Thieblemont C, Tilly H, Bieska G, Asikanius E, Carlile D, Birkett J, Pisa P, Cartron G. Salles G, et al. Blood. 2012 May 31;119(22):5126-32. doi: 10.1182/blood-2012-01-404368. Epub 2012 Mar 19. Blood. 2012. PMID: 22431570 Clinical Trial.
A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies.
Sehn LH, Assouline SE, Stewart DA, Mangel J, Gascoyne RD, Fine G, Frances-Lasserre S, Carlile DJ, Crump M. Sehn LH, et al. Blood. 2012 May 31;119(22):5118-25. doi: 10.1182/blood-2012-02-408773. Epub 2012 Mar 20. Blood. 2012. PMID: 22438256 Clinical Trial.